Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:3369 |
Name | Ewing sarcoma |
Definition | A connective tissue cancer that has_material_basis_in neural crest cells derives_from undeveloped, undifferentiated neuroectoderm. |
Source | DiseaseOntology.org |
Alt Ids | DOID:4392 DOID:4390 DOID:0050607 DOID:4980 DOID:4158 DOID:4391 |
Path | disease disease of cellular proliferation cancer organ system cancer musculoskeletal system cancer connective tissue cancer Ewing sarcoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
FGFR1 amp | Ponatinib | Ewing sarcoma | predicted - sensitive | detail... |
MLH1 negative | Pembrolizumab | Ewing sarcoma | sensitive | detail... |
MSH6 negative | Pembrolizumab | Ewing sarcoma | sensitive | detail... |
PIK3CA mutant | Irinotecan + Temozolomide + Temsirolimus | Ewing sarcoma | predicted - sensitive | detail... |
PIK3CA mutant | Temsirolimus | Ewing sarcoma | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00020566 | Phase III | Busulfan + Melphalan Dactinomycin + Doxorubicin + Etoposide + Ifosfamide + Vincristine Sulfate | Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma | Unknown status | USA | NZL | CAN | AUS | 1 |
NCT00084695 | Phase II | Fludarabine Busulfan + Melphalan anti-thymocyte globulin Cyclophosphamide Prednisone | Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases | Unknown status | USA | 0 |
NCT00089245 | Phase I | Omburtamab I-131 | Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer | Terminated | USA | 0 |
NCT00720785 | Phase I | Bortezomib | Natural Killer Cells and Bortezomib to Treat Cancer | Completed | USA | 0 |
NCT01241162 | Phase I | Decitabine | Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma | Completed | USA | 0 |
NCT01286987 | Phase I | Talazoparib | Study of BMN 673, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors | Completed | USA | GBR | 0 |
NCT01331135 | Phase I | Sirolimus | Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors | Completed | USA | 0 |
NCT01396408 | Phase II | Temsirolimus Sunitinib | A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours | Active, not recruiting | CAN | 0 |
NCT01661400 | Phase I | Cyclophosphamide Thalidomide | Anti-Angiogenic Therapy Post Transplant (ASCR) for Relapsed and Refractory Pediatric Solid Tumors | Completed | USA | 0 |
NCT01858168 | Phase I | Olaparib + Temozolomide | Phase I Study of Olaprib and Temozolomide for Ewings Sarcoma | Active, not recruiting | USA | 0 |
NCT01946529 | Phase II | Cyclophosphamide + Doxorubicin + Etoposide + Ifosfamide + Vincristine Sulfate Bevacizumab + Cyclophosphamide + Doxorubicin + Etoposide + Ifosfamide + Irinotecan + Sorafenib + Temozolomide + Temsirolimus + Vincristine Sulfate | Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors | Active, not recruiting | USA | 0 |
NCT02013336 | Phase I | Cyclophosphamide + Liposomal irinotecan | Phase 1 Study of MM-398 Plus Cyclophosphamide in Pediatric Solid Tumors | Unknown status | USA | 0 |
NCT02044120 | Phase I | Niraparib + Temozolomide | ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide in Patients With Previously Treated, Incurable Ewing Sarcoma | Completed | USA | GBR | 0 |
NCT02048371 | Phase II | Regorafenib | A Blanket Protocol to Study Oral Regorafenib in Patients With Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing/Ewing-like Sarcomas | Completed | USA | 0 |
NCT02100891 | Phase II | Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors | Completed | USA | 0 | |
NCT02116777 | Phase Ib/II | Talazoparib + Temozolomide | BMN-673 and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies | Completed | USA | 0 |
NCT02173093 | Phase Ib/II | Aldesleukin + GD2Bi-aATC + Sargramostim | Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma | Unknown status | USA | 0 |
NCT02306161 | Phase II | Cyclophosphamide + Doxorubicin + Etoposide + Ifosfamide + Vincristine Sulfate Ganitumab | Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma | Active, not recruiting | USA | CAN | 1 |
NCT02454972 | Phase II | Lurbinectedin | Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors | Completed | USA | SWE | ITA | GBR | FRA | ESP | DEU | CHE | BEL | 0 |
NCT02601950 | Phase II | Tazemetostat | A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma | Completed | USA | ITA | GBR | FRA | DEU | CAN | BEL | AUS | 1 |
NCT02644460 | Phase I | Abemaciclib | Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors | Completed | USA | 0 |
NCT02657005 | Phase I | TK216 | TK216 in Patients With Relapsed or Refractory Ewing Sarcoma | Terminated | USA | 0 |
NCT02748135 | Phase Ib/II | TB-403 | A Two-Part Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma | Completed | USA | 0 |
NCT02789228 | Phase I | MultiTAA-specific T cells | Research Study Utilizing Expanded Multi-antigen Specific Lymphocytes for the Treatment of Solid Tumors (REST) | Active, not recruiting | USA | 0 |
NCT02867592 | Phase II | Cabozantinib | Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors | Active, not recruiting | USA | 0 |
NCT02890758 | Phase I | Nogapendekin alfa inbakicept | Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 | Completed | USA | 0 |
NCT02982941 | Phase I | MGA271 | Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors | Completed | USA | 0 |
NCT03139331 | Phase I | Irinotecan + Pazopanib + Temozolomide | PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma | Completed | USA | 0 |
NCT03155620 | Phase II | Tazemetostat Larotrectinib LY3023414 Vemurafenib Palbociclib Olaparib Ulixertinib Erdafitinib Selumetinib Ensartinib | Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) | Recruiting | USA | CAN | AUS | 1 |
NCT03190174 | Phase Ib/II | Nab-rapamycin + Nivolumab | Nivolumab (Opdivo) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma | Completed | USA | 0 |
NCT03210714 | Phase II | Erdafitinib | Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) | Active, not recruiting | USA | 1 |
NCT03213678 | Phase II | LY3023414 | Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) | Active, not recruiting | USA | 1 |
NCT03213704 | Phase II | Larotrectinib | Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) | Active, not recruiting | USA | 1 |
NCT03221400 | Phase Ib/II | STA-8666 | PEN-866 in Patients With Advanced Solid Malignancies | Unknown status | USA | 0 |
NCT03233204 | Phase II | Olaparib | Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) | Completed | USA | 1 |
NCT03245151 | Phase Ib/II | Everolimus + Lenvatinib | Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors | Completed | USA | CAN | 0 |
NCT03441360 | Phase II | Eribulin | Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS) | Completed | USA | 0 |
NCT03458728 | Phase Ib/II | Copanlisib | Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients | Terminated | USA | 0 |
NCT03495921 | Phase III | FANG vaccine + Irinotecan + Temozolomide Irinotecan + Temozolomide | Vigil + Irinotecan and Temozolomide in Ewing's Sarcoma (VITA) | Terminated | USA | 0 |
NCT03514407 | Phase I | INCB059872 | A Study of INCB059872 in Relapsed or Refractory Ewing Sarcoma | Terminated | USA | ITA | GBR | ESP | 0 |
NCT03585465 | Phase Ib/II | Capecitabine + Cyclophosphamide + Nivolumab + Vinblastine Capecitabine + Cyclophosphamide + Vinblastine Cyclophosphamide + Nivolumab + Vinblastine Capecitabine + Nivolumab | Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors | Active, not recruiting | FRA | BEL | 0 |
NCT03600649 | Phase I | Seclidemstat | Clinical Trial of SP-2577 in Patients With Relapsed or Refractory Ewing Sarcoma | Active, not recruiting | USA | 0 |
NCT03698994 | Phase II | Ulixertinib | Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) | Active, not recruiting | USA | 1 |
NCT03709680 | Phase I | Irinotecan + Palbociclib + Temozolomide | Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors | Active, not recruiting | USA | TUR | SWE | SVK | POL | NLD | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BGR | BEL | ARG | 2 |
NCT03778996 | Phase II | Methoxsalen + Phenytoin + Sirolimus + SM88 | SM-88 as Maintenance Therapy for Advanced Ewing's Sarcoma Patients and as Salvage Therapy for Sarcoma Patients (HopES) | Active, not recruiting | USA | 0 |
NCT03880123 | Phase I | Ixazomib + Selinexor | Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma | Withdrawn | USA | 0 |
NCT04067115 | Phase Ib/II | Irinotecan + Trabectedin | SARC037: A Phase I/II Study to Evaluate the Safety of Trabectedin in Combination With Irinotecan in Ewing Sarcoma Patients (U01CA236220) | Active, not recruiting | USA | 0 |
NCT04129151 | Phase II | Ganitumab + Palbociclib | Palbociclib + Ganitumab In Ewing Sarcoma | Terminated | USA | 0 |
NCT04183062 | Phase II | BIO-11006 + Docetaxel + Gemcitabine | BIO-11006 for Osteosarcoma and Ewing's Sarcoma Lung Metastases | Withdrawn | USA | 0 |
NCT04205227 | Phase Ib/II | ENB003 + Pembrolizumab | ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors | Active, not recruiting | USA | AUS | 0 |
NCT04469530 | Phase II | Celecoxib + Cyclophosphamide + Etoposide + Sirolimus | Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors (AflacST1903) | Recruiting | USA | 0 |
NCT04544995 | Phase I | Dostarlimab-gxly + Niraparib | Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Pediatric Participants With Solid Tumors | Recruiting | HUN | GBR | FRA | ESP | DEU | CZE | 0 |
NCT04593758 | Phase Ib/II | CPI-613 + Hydroxychloroquine | To Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy of CPI-613 (Devimistat) Plus Hydroxychloroquine in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft Tissue | Completed | USA | 0 |
NCT04661852 | Phase I | Cabozantinib + Cyclophosphamide + Pegfilgrastim + Topotecan Cabozantinib + Cyclophosphamide + Filgrastim + Topotecan | Cabozantinib With Topotecan-Cyclophosphamide | Completed | USA | 0 |
NCT04851119 | Phase Ib/II | BC2059 | Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors | Recruiting | USA | 0 |
NCT04890093 | Phase Ib/II | STA-8666 + Temozolomide + Vincristine Sulfate | Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors | Recruiting | USA | 0 |
NCT04901702 | Phase Ib/II | Irinotecan + Temozolomide Irinotecan + Talazoparib | Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma | Active, not recruiting | USA | CAN | 0 |
NCT04906876 | Phase II | Docetaxel + Elraglusib + Gemcitabine | 9-ING-41Combined With Chemotherapy in Adolescents and Adults | Withdrawn | USA | 0 |
NCT05064306 | Expanded access | Omburtamab I-131 | 131I-omburtamab for the Treatment of Central Nervous System/Leptomeningeal Neoplasms in Children and Young Adults | Available | USA | 0 |
NCT05071209 | Phase Ib/II | Elimusertib | Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors | Active, not recruiting | USA | CAN | 0 |
NCT05093322 | Phase Ib/II | Gemcitabine + Surufatinib | A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors | Completed | USA | 0 |
NCT05116800 | Phase II | Docetaxel + Elraglusib + Gemcitabine | Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma | Withdrawn | USA | 0 |
NCT05131386 | Phase II | Dexamethasone + Trabectedin | Multicohort Trial of Trabectedin and Low-dose Radiation Therapy in Advanced/Metastatic Sarcomas (SYNERGIAS) | Recruiting | ESP | 0 |
NCT05135975 | Phase II | Cabozantinib | A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors | Recruiting | USA | 0 |
NCT05182164 | Phase II | Cabozantinib + Pembrolizumab | Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas (PEMBROCABOSARC) | Recruiting | FRA | 0 |
NCT05253131 | Phase Ib/II | AZD5153 + Durvalumab + Selumetinib AZD5153 + Selumetinib | Trial of Selumetinib and AZD5153 With Durvalumab for Sarcomas | Not yet recruiting | USA | 0 |
NCT05275426 | Phase II | Gemcitabine + LY2880070 | A Study of LY2880070 and Gemcitabine in People With Ewing Sarcoma,Ewing-Like Sarcoma, and Desmoplastic Small Round Cell Tumor | Recruiting | USA | 0 |
NCT05302921 | Phase II | Ipilimumab + Nivolumab | Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors | Active, not recruiting | USA | 0 |
NCT05389462 | Phase I | ADCT-601 + Gemcitabine ADCT-601 | A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors | Recruiting | USA | GBR | FRA | ESP | 0 |
NCT05440786 | Phase II | Irinotecan + Temozolomide Abemaciclib + Irinotecan + Temozolomide | CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma | Recruiting | USA | ITA | FRA | ESP | DEU | AUS | 1 |
NCT05605522 | Phase I | 225Ac-FPI-2059 | A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours | Recruiting | USA | AUS | 0 |
NCT05830084 | Phase I | Cyclophosphamide + Etoposide + Ifosfamide + Regorafenib + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Etoposide + Ifosfamide + Regorafenib + Vincristine Sulfate Busulfan + Melphalan | Phase Ib / Regorafenib With Conventional Chemotherapy/Newly Diagnosed Patients/ Multimetastatic Ewing Sarcoma (REGO-EWING) | Recruiting | NLD | ITA | FRA | ESP | DNK | AUS | 0 |
NCT05841563 | Phase I | PM54 | Clinical Trial of PM54 in Advanced Solid Tumors Patients. | Recruiting | USA | ESP | BEL | 0 |
NCT05918640 | Phase Ib/II | Lurbinectedin | Lurbinectedin in FET-Fused Tumors (LiFFT) | Recruiting | USA | 0 |
NCT05968768 | Phase II | Naxitamab | To Evaluate the Efficacy and Safety of Naxitamab in Patients With Refractory Ewing's Sarcoma (Butterfly) | Recruiting | POL | 0 |
NCT06047977 | Phase I | Cyclophosphamide + Fludarabine Aldesleukin + tumor infiltrating lymphocytes | Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid Tumors | Not yet recruiting | USA | 0 |
NCT06094101 | Phase Ib/II | Peptide vaccine IPX | Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision) (PerVision) | Recruiting | DEU | 0 |
NCT06156410 | Phase I | Cabozantinib + Ifosfamide | Cabozantinib With Ifosfamide in Ewing's Sarcoma and Osteosarcoma | Recruiting | USA | 0 |
NCT06395103 | Phase Ib/II | VLS-101 | Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) | Recruiting | USA | ISR | GBR | ESP | BRA | 2 |
NCT06541262 | Phase Ib/II | Irinotecan + Silmitasertib + Temozolomide + Vincristine Sulfate Irinotecan + Silmitasertib + Temozolomide | Silmitasertib (CX-4945) in Combination with Chemotherapy for Relapsed Refractory Solid Tumors | Recruiting | USA | 0 |
NCT06566092 | Phase I | Lifileucel LN-145 | Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants | Recruiting | USA | 0 |